ArticleBiomedicines2020
Exploring the Role of Gut Microbiota in Major Depressive Disorder and in Treatment Resistance to Antidepressants.
Article in Biomedicines, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 72 citations in OpenAlex.
- Gut microbiota composition in depressive disorder: a systematic review, meta-analysis, and meta-regression.Translational psychiatry · 2023Pooled it
- Systematic review of probiotics as an adjuvant treatment for psychiatric disorders.Frontiers in behavioral neuroscience · 2023Pooled it
- The Role of Gut Microbiota in Neuropsychiatric Diseases - Creation of An Atlas-Based on Quantified Evidence.Frontiers in cellular and infection microbiology · 2022Pooled it
- Microbes and medicines: interrelationships between pharmaceuticals and the gut microbiome.Gut microbes · 2026Review
- Probiotic microcapsule polysaccharide-protein composite system: construction, mechanism and application.Archives of microbiology · 2026Review
- Reproducible Gut Microbiome Alterations in Major Depressive Disorder: A Systematic Review of Taxonomic and Functional Findings.Epidemiologia (Basel, Switzerland) · 2026Review
- Mapping the reciprocal interactions between antidepressants and the gut microbiome: novel targets for the personalisation and optimization of drug response.Molecular psychiatry · 2026Review
- Article
- Clinical relevance of loneliness in the treatment of depression: study protocol for a naturalistic prospective longitudinal study.Frontiers in psychiatry · 2026Article
- Brain-bone axis dysregulation: Biological code underlying the bidirectional association between depression and musculoskeletal disorders.Journal of orthopaedic translation · 2026Review
- Altered gut microbial diversity, composition, and metabolomic potential in patients with major depressive disorder and recent suicide attempt.Brain, behavior, & immunity - health · 2025Article
- Comparative analysis of the risk of severe bacterial infection and septicemia in adolescents and young adults with treatment-resistant depression and treatment-responsive depression - a nationwide cohort study in Taiwan.European child & adolescent psychiatry · 2025Observational
- Article
- Relationships of Personality Traits With the Taxonomic Composition of the Gut Microbiome Among Psychiatric Inpatients.The Journal of neuropsychiatry and clinical neurosciences · 2025Article
- The bidirectional interaction between antidepressants and the gut microbiota: are there implications for treatment response?International clinical psychopharmacology · 2025Review
- The microbiota-gut-brain axis in depression: unraveling the relationships and therapeutic opportunities.Frontiers in immunology · 2025Review
- Zuojinwan ameliorates depressive-like behavior and gastrointestinal dysfunction in mice by modulating the FXR-bile acid-gut microbiota pathway.Frontiers in microbiology · 2025Article
- Healthy human gut microbiome: Towards standardized research.AIMS microbiology · 2025Review
- Article
- Baseline gut microbiota profiles affect treatment response in patients with depression.Frontiers in microbiology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major depressive disorder (MDD) is a common severe psychiatric illness, exhibiting sub-optimal response to existing pharmacological treatments. Although its etiopathogenesis is still not completely understood, recent findings suggest that an altered composition of the gut microbiota might play a role. Here we aimed to explore potential differences in the composition of the gut microbiota between patients with MDD and healthy controls (HC) and to identify possible signatures of treatment response by analyzing two groups of MDD patients characterized as treatment-resistant (TR) or responders (R) to antidepressants. Stool samples were collected from 34 MDD patients (8 TR, 19 R and 7 untreated) and 20 HC. Microbiota was characterized using the 16S metagenomic approach. A penalized logistic regression analysis algorithm was applied to identify bacterial populations that best discriminate the diagnostic groups. Statistically significant differences were identified for the families of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.